Clinical Trial Update: A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma [Phase 3]

View source ↗

Summary

Novartis is conducting a Phase 3 trial comparing tisagenlecleucel to standard of care in adults with relapsed/refractory follicular lymphoma. The study is curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Kymriah (tisagenlecleucel)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Follicular Lymphoma (FL) | Phase 3 | Status: ACTIVE_NOT_RECRUITING